Cohance Lifesciences Stock Forecast

Stock Price Forecast

According to 9 analysts polled by S&P Global, Cohance Lifesciences stock has a consensus rating of "Hold" and an average price target of ₹516.78. The average 1-year stock price forecast is 27.33% higher than the current stock price, while the lowest is ₹300.00 (-26.08%) and the highest is ₹1,150 (+183.36%).

Price Target: ₹516.78 (+27.33%)

Analyst Consensus: Hold

Target	Low	Average	Median	High
Price	₹300.00	₹516.78	₹440.00	₹1,150
Change	-26.08%	+27.33%	+8.41%	+183.36%

* Price targets were last updated on May 14, 2026.

Analyst Ratings

The average analyst rating for Cohance Lifesciences stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Apr '26	May '26	Jun '26
Strong Buy	5	5	5	5	4	4
Buy	1	1	1	1	0	0
Hold	2	2	3	3	1	1
Sell	1	1	0	0	2	2
Strong Sell	0	0	0	0	2	2
Total	9	9	9	9	9	9

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Alok Dalal Jefferies	Jefferies	Sell Downgrades ₹300.00	Sell	Downgrades	₹300.00	-26.08%	May 14, 2026

Financial Forecast

Revenue This Year

26.29B

from 22.69B

15.89%

from 22.69B

Revenue Next Year

31.07B

from 26.29B

18.19%

from 26.29B

EPS This Year

7.06

from 5.24

34.85%

from 5.24

EPS Next Year

10.65

from 7.06

50.72%

from 7.06

Fiscal Year	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Mar 31, 2022	Mar 31, 2023	Mar 31, 2024	Mar 31, 2025	Mar 31, 2026	Mar 31, 2027
Revenue	13.20B	13.40B	10.51B	26.09B	22.69B	26.29B
Revenue Growth	30.75%	1.52%	-21.56%	148.11%	-13.03%	15.89%
Gross Profit	7.46B	7.52B	6.80B	17.92B	16.06B	18.65B
Gross Margin	56.51%	56.11%	64.65%	68.70%	70.79%	70.95%
Operating Income	5.42B	5.26B	3.54B	6.30B	2.40B	3.44B
Net Income	4.54B	4.11B	3.00B	4.87B	1.79B	2.78B
EPS	-	-	-	-	5.24	7.06
EPS Growth	-	-	-	-	-49.88%	34.85%
Forward PE	30.48	26.23	44.40	80.68	80.68	57.46
Dividend / Share	2.00	3.00	-	-	-	-
Free Cash Flow	1.03B	1.08B	2.97B	-3.61B	485.73M	1.24B
No. Analysts	-	-	-	-	-	9

EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.

Revenue Forecast

Revenue	2027	2028	2029
High	35.5B
Avg	26.3B
Low	24.0B

Revenue Growth

Revenue Growth	2027	2028	2029
High	56.5%
Avg	15.9%
Low	5.9%

EPS Forecast

EPS	2027	2028	2029
High	8.50
Avg	7.06
Low	6.01

EPS Growth

EPS Growth	2027	2028	2029
High	62.3%
Avg	34.8%
Low	14.7%